Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 324-329

  Rose, Peter G ^a   Tian, Chunqiao ^b   Bookman, Michael A ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Disease control; Ovarian carcinoma; Platinum resistant; Progression free; Response; Survival

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ALTRETAMINE; CISPLATIN; CYCLOSPORIN; DOCETAXEL; GEMCITABINE; LEDOXANTRONE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; VALSPODAR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PLATINUM RESISTANT OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENDPOINT DETERMINATION; FEMALE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950187271     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.040     Document Type: Article

References (31)

1. Markman M., and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10 (1992) 513-514
2. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
3. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
4. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
5. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 (2000) 26-35
6. Cesano A., Lane S.R., Poulin R., Ross G., and Fields S.Z. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15 (1999) 1233-1238
7. Gronlund B., Høgdall C., Christensen I.J., Engelholm S.A., and Hansen H.H. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with paclitaxel-platinum?. Gynecol Oncol 94 (2004) 409-415
8. Manetta A., Blessing J.A., and Hurteau J.A. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 68 (1998) 45-46
9. Markman M., Blessing J.A., Moore D., and Lentz S.S. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 69 (1998) 226-229
10. Plaxe S.C., Blessing J.A., Morgan M.A., and Carlson J. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am J Clin Oncol 25 (2002) 45-47
11. Fracasso P.M., Brady M.F., Moore D.H., Walker J.l., Rose P.G., Letvak L., et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19 (2001) 2975-2982
12. Hoffman M.A., Blessing J.A., and Morgan M. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 79 (2000) 463-465
13. Markman M., Blessing J.A., DeGeest K., Morgan M., Look K.Y., Herzog T.J., et al. Lack of Efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial. Gynecol Oncol 75 (1999) 444-446
14. Miller D.S., Blessing J.A., Waggoner S., Schilder J., Sorosky J., Bloss J., et al. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 96 (2005) 67-71
15. Rose P.G., Blessing J.A., Ball H.G., Hoffman J., Warshal D., DeGeest K., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88 (2003) 130-135
16. Fracasso P.M., Blessing J.A., Morgan M.A., Sood A.K., and Hoffman J.S. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group study. J Clin Oncol 21 (2003) 2856-2859
17. Brewer C.A., Blessing J.A., Nagourney R.A., Morgan M., and Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103 (2006) 446-450
18. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101 (2006) 436-440
19. Lara P.N., Redman M.W., Kelly K., Edelman M.J., Williamson S.K., Crowley J.J., et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomixed trials. J Clin Oncol 26 (2008) 463-467
20. Bruzzi P., Del Mastro L., Sormani M.P., Bastholt L., Danova M., Focan C., et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23 (2005) 5117-5125
21. Anderson J.R., Cain K.C., and Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1 (1983) 710-719
22. Simon R., and Makuch R.W. A non-parametric graphic presentation of the relationship between survival and the occurrence of an event: application to responders versus non-responder bias. Stat Med 3 (1984) 35-44
23. Winter W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 25 (2007) 3621-3627
24. Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol 21 (2003) 3013-3015
25. Prefontaine M., Gelfand A.T., Donovan J.T., and Powell J.L. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol 55 (1994) 87-90
26. Gwyther S., Bolis G., Gore M., ten Bokkel Huinink W., Verweij J., Hudson I.R., et al. Experience with independent radiological review during a Topotecan trial in ovarian cancer. Ann Oncol 8 (1997) 463-468
27. Kaye SB P.M., Aapro M., Kavanagh J., EORTC Early Clinical Trials Group and Clinical Screening Group, and and the MD Anderson Cancer Center. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer 31A Suppl 4 (1995) S14-S17
28. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18 (2000) 106-115
29. Gordon A.N., Tonda M., Sun S., Rackoff W., and Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8
30. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
31. Goonewardene T.I., Hall M.R., and Rustin G.J. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 8 (2007) 813-821